The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Oct. 10, 2016
Applicant:

Ibc Pharmaceuticals, Inc., Morris Plains, NJ (US);

Inventors:

Chien-Hsing Chang, Downingtown, PA (US);

David M. Goldenberg, Mendham, NJ (US);

Edmund A. Rossi, Woodland Park, NJ (US);

Diane Rossi, Woodland Park, NJ (US);

Hans J. Hansen, Diamondhead, MS (US);

Assignee:

IBC Pharmaceuticals, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/18 (2006.01); A61K 38/21 (2006.01); A61K 47/42 (2017.01); A61K 45/06 (2006.01); A61K 38/19 (2006.01); C07K 16/40 (2006.01); C07K 16/32 (2006.01); C07K 16/44 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 38/45 (2006.01); C07K 14/47 (2006.01); C07K 16/46 (2006.01); C07K 14/00 (2006.01); C12N 9/12 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 9/0019 (2013.01); A61K 38/1709 (2013.01); A61K 38/195 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); A61K 38/45 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/42 (2013.01); A61K 47/60 (2017.08); A61K 47/64 (2017.08); C07K 14/001 (2013.01); C07K 14/4702 (2013.01); C07K 16/283 (2013.01); C07K 16/2803 (2013.01); C07K 16/2806 (2013.01); C07K 16/289 (2013.01); C07K 16/2809 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2833 (2013.01); C07K 16/2842 (2013.01); C07K 16/2845 (2013.01); C07K 16/2851 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 16/2884 (2013.01); C07K 16/2887 (2013.01); C07K 16/2893 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/3053 (2013.01); C07K 16/3076 (2013.01); C07K 16/3092 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 16/44 (2013.01); C07K 16/468 (2013.01); C12N 9/12 (2013.01); C12Y 207/11011 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/735 (2013.01); C07K 2319/74 (2013.01); C07K 2319/75 (2013.01); C12Y 207/11001 (2013.01); Y02A 50/466 (2018.01);
Abstract

The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.


Find Patent Forward Citations

Loading…